A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects
Latest Information Update: 18 Apr 2024
At a glance
- Drugs SBP-9330 (Primary)
- Indications Smoking withdrawal
- Focus Adverse reactions; First in man
- Sponsors Camino Pharma
- 06 Feb 2024 According to a Camino Pharma Media Release, Phase 1 clinical testing of SBP-9330 was completed under a previous $11.4-million, 3-year NIDA grant.
- 06 Feb 2024 Results presented in a Camino Pharma Media Release.
- 06 Apr 2023 Status changed from recruiting to completed.